Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
Other Sizes |
|
Targets |
Ki: 44.4 nM (rat A2A), 360 nM (human A2A), ≥10000 nM (rat A1) and 541 nM (human A1)[1]
|
---|---|
ln Vitro |
Compound 7, PSB 0777 ammonium hydrate, exhibits significant selectivity (>225-fold) for the A2AAR relative to the other AR subtypes (Ki values of ≫10000 for the human A3 receptor and >10000 nM for the human A2B receptor, respectively). In CHO-K1 cells, PSB 0777 ammonium hydrate exhibits full agonistic activity at A2AAR, with an EC50 value of 117 nM[1]. Human β1 (Ki = 4.4 μM) and β3 (Ki = 3.3 μM) adrenergic receptors are bound by PSB-0777 ammonium[2]. In untreated and inflamed rat ileum/jejunum preparations, PSB 0777 ammonium hydrate (0.1 µM, 1 µM, and 10 µM) enhances concentration-dependently Acetylcholine (Ach, 1 mM) contractions[1].
|
ln Vivo |
Ammonium hydrate (0.4 mg/kg/day; oral gavage; day 5 to day 10) administered via PSB 0777 results in a significant decrease in the infiltration of inflammatory cells and an improvement in the architecture of the colonic mucosa[3]. C57BL/6J mice are susceptible to dose-dependent hypothermia and hypoactivity when exposed to PSB 0777 ammonium hydrate (0.03, 0.3, and 3 mg/kg; ip)[2]. After being taken orally, PSB 0777 ammonium hydrate cannot be absorbed systemically by the mucosa of the digestive tract. Rats treated with PSB 0777 ammonium hydrate (0.4 mg/kg/day; PO) had very low plasma concentrations at 30 minutes (less than 5 nM) and no plasma concentrations at 60 minutes. Ammonium hydrate PSB 0777 (0.4 mg/kg/day; IP) produces plasma concentrations that are clearly visible after 30 minutes, start to decline after 60 minutes, and become undetectable after 120 and 240 minutes[3].
|
References |
[1]. Ali El-Tayeb, et al. Development of Polar Adenosine A2A Receptor Agonists for Inflammatory Bowel Disease: Synergism with A2B Antagonists. ACS Med Chem Lett. 2011 Oct 10;2(12):890-5.
[2]. Jesse Lea Carlin, et al.Activation of adenosine A 2A or A 2B receptors causes hypothermia in mice. Neuropharmacology. 2018 Sep 1;139:268-278. [3]. L Antonioli, et al. Anti-inflammatory effect of a novel locally acting A 2A receptor agonist in a rat model of oxazolone-induced colitis. Purinergic Signal. 2018 Mar;14(1):27-36. |
Molecular Formula |
C18H20N5O7S2.NH4.1.75H2O
|
---|---|
Molecular Weight |
532.09
|
Related CAS # |
PSB 0777 ammonium;2122196-16-9
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.8794 mL | 9.3969 mL | 18.7938 mL | |
5 mM | 0.3759 mL | 1.8794 mL | 3.7588 mL | |
10 mM | 0.1879 mL | 0.9397 mL | 1.8794 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.